Repetitive stability study of remdesivir/cyclodextrin complex on the international space station by György Dormán, Balázs Buchholcz, István Puskás, Pál Szabó, Erzsébet Varga, Lajos Szente, György M. Keserű, Ferenc Darvas

Subjects: “…Remdesivir sulfobutylether-beta-cyclodextrin…”
Get full text

Assessment of asymptomatic fungal infections in COVID-19 positive and COVID-19 negative pneumonia: A comprehensive epidemiological analysis by Dheerendra Kumar Mishra, Pramod Kushwaha, Pooja Gangwar, Ajeet Singh, Umesh Pratap Singh

“…Furthermore, COVID-19-positive patients exhibited distinct clinical characteristics, including increased use of remdesivir (94%), higher rates of invasive mechanical ventilation (36%), and a prolonged hospital stay (14.29 days). …”
Get full text

Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection. by Bryce M Warner, Robert Vendramelli, Amrit S Boese, Jonathan Audet, Nikesh Tailor, Courtney Meilleur, Nathan Glowach, Marnie Willman, Thang Truong, Estella Moffat, Kevin Tierney, Beata Kosak, Irfan Dhanidina, Jarret Engstrom, Bozena Korczak, Ian McGowan, Carissa Embury-Hyatt, Darwyn Kobasa

“…Daily treatment with OB-002 altered immune gene transcription in the lungs, and reduced pathology following infection, but did not prevent weight loss or viral replication in the lungs of infected animals, even in combination with the antiviral drug remdesivir. Our data suggest that targeting the CCR5-CCL5 pathway in SARS-CoV-2 infection in hamsters is insufficient to significantly impact disease development in this model.…”
Get full text

Antivirals for the treatment of mild and moderate COVID-19 in South Africa by R Perumal, V Naidoo, S Govender, T N Gengiah

“…COVID‐19 antivirals such as remdesivir, nirmatrelvir/ ritonavir and molnupiravir are safe and cost‐effective and have received either full approval or emergency use authorisation from regulators. …”
Get full text

Improving clinical care of patients in Nipah outbreaks: moving beyond ‘compassionate use’ by Md Zakiul Hassan, Amanda Rojek, Piero Olliaro, Peter Horby

“…Current care relies on supportive measures and the ‘compassionate use’ of unapproved drugs like ribavirin and remdesivir. Drugs used ‘off-label’ during outbreaks can become the ‘standard of care’ without robust evidence of their safety or efficacy, complicating the testing of new therapies and perpetuating uncertainty about their true effectiveness. …”
Get full text